Boston Scientific (BSX) Stock
Global medical device maker for heart and surgical care. Here's the price, business snapshot, and what's worth knowing about Boston Scientific in October 2026.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It’s Moving
Boston Scientific Defies Market Slump as New COO Appointment Signals Operational Efficiency Push
- The company appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, introducing a new operating structure designed to increase efficiency.
- BSX stock advanced by +1.64% on October 9 to reach $42.73, reflecting positive investor sentiment toward the recent corporate developments.
- On October 8, shares rose +1.11% to close at $42.04, demonstrating strength even as the wider market declined.
Boston Scientific Defies Market Slump as New COO Appointment Signals Operational Efficiency Push
- The company appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, introducing a new operating structure designed to increase efficiency.
- BSX stock advanced by +1.64% on October 9 to reach $42.73, reflecting positive investor sentiment toward the recent corporate developments.
- On October 8, shares rose +1.11% to close at $42.04, demonstrating strength even as the wider market declined.
Sixth Month Growth Performance
When is the next earnings date for BOSTON SCIENTIFIC CORP (BSX)?
No confirmed upcoming earnings date has been announced for Boston Scientific as of October 12, 2026. Based on the historical reporting pattern where the company typically releases results approximately three months after the prior quarter's close, the next report is expected in late January 2027. This anticipated release will cover the fourth quarter and full fiscal year 2026 performance. Investors should monitor official corporate communications for the precise scheduling confirmation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific's stock with a target price of $80.75, indicating significant growth potential.
Financial Health
Boston Scientific is performing well with solid revenue, profits, and cash flow, indicating strong financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
